Insulin Glargine (Lantus)

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Also Known As:

Lantus; A21-Gly-B31-Arg-B32-Arg-insulin; Basaglar; Glargine; HOE 901; HOE-901; Insulin, Gly(A21)-Arg(B31,B32); Insulin, Glycyl(A21)-Arginyl(B31,B32); Lantus Solostar; 901, HOE; A21 Gly B31 Arg B32 Arg insulin; Glargine, Insulin; Glargine-aglr, Insulin; HOE901; Solostar, Lantus; Insulin Glargine-aglr; Insulin Glargine-yfgn; Rezvoglar; Semglee

Networked: 1898 relevant articles (232 outcomes, 790 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Rosenstock, Julio: 48 articles (01/2022 - 11/2003)
2.	Bolli, Geremia B: 34 articles (01/2021 - 07/2002)
3.	Gerstein, Hertzel C: 26 articles (01/2022 - 11/2007)
4.	Bergenstal, Richard M: 24 articles (11/2021 - 03/2008)
5.	Buse, John B: 24 articles (11/2021 - 06/2009)
6.	Niemoeller, Elisabeth: 20 articles (11/2022 - 11/2016)
7.	Bolli, G B: 19 articles (01/2020 - 11/2004)
8.	Souhami, Elisabeth: 18 articles (11/2022 - 09/2013)
9.	Riddle, Matthew C: 18 articles (01/2019 - 11/2003)
10.	Home, P D: 18 articles (09/2018 - 11/2001)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 02/01/2006 - "Insulin glargine in combination with educational support and close clinical supervision significantly improved metabolic control without significant weight change in patients with Type 2 diabetes in clinical practice over 30 months. " 01/01/2007 - "Long-term treatment with BIAsp 70/30 was projected to be cost-effective for patients with type 2 diabetes insufficiently controlled on OADs alone compared to glargine. " 01/01/2018 - "Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U/mL: results of the observational OPTIN-D study." 03/01/2017 - "This trial demonstrated comparable efficacy with noninferior HbA1c and comparable safety of once-daily IDeg using either a simple or stepwise titration algorithm in Japanese patients with type 2 diabetes inadequately controlled with insulin glargine." 01/01/2017 - "Compared with glargine U100 treatment, glargine U300 treatment improved the MODD as assessed by CGM in type 2 diabetes patients. "
2.	Hypoglycemia (Reactive Hypoglycemia) 01/01/2019 - "Gla-300 demonstrated efficacy and tolerability comparable to glargine U100, with a significant decrease in the risk of hypoglycemia, at night and in 24 hours, providing greater flexibility in the injection schedule, with a window of 6 hours. " 05/01/2014 - "Reductions in HbA1c level and hypoglycemia rates were significantly greater with glargine use than with intensification of OADs or lifestyle modifications, overall, and in patients with any CVRF. " 05/01/2003 - "Insulin glargine has been associated with less nocturnal hypoglycemia and improved treatment satisfaction in several clinical trials with durations of < 52 weeks. " 01/01/2021 - "NO. Insulin glargine may lead to less patient-reported, symptomatic, and nocturnal hypoglycemia, although overall, there may not be a difference in the risk for severe hypoglycemia orhypoglycemiarelated emergency department (ED) visits and hospitalizations (strength of recommendation [SOR]: B, systematic review of randomized controlled trials [RCTs], individual RCTs, and observational study)." 10/19/2020 - "There was no difference in episodes of hypoglycemia (very low-quality evidence) and while there was no difference reported in QoL, all participants opted to continue treatment with glargine after the trial was completed. "
3.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/01/2004 - "Our principal aim in this short-term study was to compare the efficacy of CSII to MDI with glargine in lowering HbA(1c) levels in children and adolescents with type 1 diabetes. " 11/01/2007 - "The rate of improvement in metabolic control in children with diabetes mellitus type 1 on insulin glargine depends on age." 03/10/2023 - "Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades." 12/01/2022 - "A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short-term study." 02/01/2021 - "Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study)."
4.	Weight Gain 08/01/2010 - "In this study, treatment with insulin glargine in people with T2DM was associated with a significant reduction in HbA1c without differential increase in weight gain in obese and non-obese subgroups. " 01/01/2005 - "Better A1c reductions were obtained with premeal GLU, but postmeal administration of GLU was as safe and effective as premeal GLU or RHI in combination with insulin glargine and was not associated with weight gain." 08/01/2011 - "However, most insulin glargine studies have reported a weight gain. " 10/01/2004 - "The weight gain was significantly higher in the NPH group at the end of the study (P = 0.004) with no significant change in the glargine group. " 02/01/2004 - "The mean (+/-SEM) A1C values were significantly reduced in both groups from the baseline to the end of the study (7.7 +/- 0.1% to 7.5 +/- 0.1% for the pump group and 8.0 +/- 0.1% to 7.7 +/- 0.1% for the insulin glargine group, P< 0.001) with similar weight gain (P> 0.05) in both groups. "
5.	Diabetes Mellitus 12/01/2012 - "Regular SC administration of insulin glargine was successful in the treatment of diabetes mellitus in the ferret of this report and may be effective for other diabetic ferrets." 01/01/2012 - "The objective of this study was to evaluate the safety and efficacy of insulin glargine in dogs with diabetes mellitus (DM). " 01/01/2022 - "This was a single-center retrospective chart review study of adult patients (e.g., ≥18 years) with diabetes mellitus (DM) who were treated with insulin glargine (Lantus®) for at least 12 months and then switched to Basaglar® for another 12 months. " 01/01/2022 - "The study aimed to evaluate the efficacy and safety of insulin glargine 300 U/ml (IGla-U300) in cats with variable duration of diabetes mellitus (DM). " 02/01/2019 - "Patients were included in the study if they were older than 18 years, received glargine before admission, and had type 1 or 2 diabetes mellitus. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Isophane Insulin (NPH Insulin)
3.	insulin degludec
4.	Glucose (Dextrose)
5.	Insulin Glargine (Lantus)
6.	Hypoglycemic Agents (Hypoglycemics)
7.	Exenatide (Byetta)
8.	Metformin (Glucophage)
9.	Liraglutide
10.	Glycated Hemoglobin (Glycosylated Hemoglobin)

Related Therapies and Procedures

1.	Glycemic Control
2.	Therapeutics
3.	Injections
4.	High-Protein Low-Carbohydrate Diet (Atkins Diet)
5.	Drug Therapy (Chemotherapy)